ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea · Delayed Price · Currency is KRW 8,500.00
-510.00 (-5.66%)
At close: Mar 19, 2026
ImmuneOncia Therapeutics Revenue
In the year 2025, ImmuneOncia Therapeutics had annual revenue of 111.21M KRW, down -83.01%.
Revenue
111.21M
Revenue Growth
-83.01%
P/S Ratio
5,808.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
645.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 111.21M | -543.33M | -83.01% |
| Dec 31, 2024 | 654.54M | 544.54M | 495.04% |
| Dec 31, 2023 | 110.00M | -7.62B | -98.58% |
| Dec 31, 2022 | 7.73B | 7.70B | 21,413.30% |
| Dec 31, 2021 | 35.95M | 33.45M | 1,337.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 385.76B |
| Myung In Pharmaceutical LTD. | 283.31B |
| DAE HWA Pharmaceutical | 149.47B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 75.60B |
| Vivozon Pharmaceutical | 66.40B |
| Organoidsciences | 2.55B |
| CellBion | 2.13B |